T-9 peptide

  • Description

  • Application Data

Description

A phage (T-9) displayed peptide found to have specific affinity for myofibers. 

See full description

Application Data

Catalogue number crb1001633
Molecular Weight 1343.6
Disease Area Muscle disorder
Sequence (three letter code)

H-Ser-Lys-Thr-Phe-Asn-Thr-His-Pro-Gln-Ser-Thr-Pro-OH

Storage -20°C
Citations

Betts et al., (2013). Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy. Curr. Pharm. Des. 19(16): 2948. PMID: 23140454.

 

Van Westering et al., (2015). Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy. Molecules20(5): 8823. PMID: 25988613.

References

Betts et al., (2013). Cell penetrating peptide delivery of splice directing oligonucleotides as a treatment for Duchenne muscular dystrophy. Curr. Pharm. Des. 19(16): 2948. PMID: 23140454.

 

Van Westering et al., (2015). Current understanding of molecular pathology and treatment of cardiomyopathy in duchenne muscular dystrophy. Molecules20(5): 8823. PMID: 25988613.

Material Safety Data Sheet (MSDS)

Duchenne muscular dystrophy is a severe muscle wasting X-linked genetic disease cause by mutations in the gene encoding the muscle structural protein, dystrophin. Exon skipping therapy remains a key approach for treatment of DMD but still requires considerable research to improve efficient and specific delivery of molecules to myofibers. Use of a phage library identified this sequence as having a high affinity for myofibers. Conjugation of this peptide to novel DMD molecules could provide the insights needed in the field. This product is produced to research grade quality and is suited for research laboratory use only.  

T-9 peptide

Cat No.Pack SizePriceQty.
£110.00
£85.00
Bulk Quote